Rendement sur 1 an (CAGR)
-15.72%
Sanofi SA Exchange (PA, EUR)
SAN.PA
71.52
-0.88 (-1.23%)
HealthcareDrug Manufacturers - General
Loading...
Rendement sur 3 ans (CAGR)
-10.47%
Rendement sur 5 ans (CAGR)
-4.22%
Rendement sur 10 ans (CAGR)
-0.52%
Adobe 3e trimestre 2026 – Le sentiment du marché influence-t-il le prix ?
Lire plusCapitalisation boursière
84.98B
Cours/chiffre d'affaires
1.77
Valeur d'entreprise
138.12B
Cours/valeur comptable
1.22
Rendement du div
0.00%
Années de croissance
-
Croissance du div
-
Versement FCF
62.02%
Trailing P/E
12.57
PEG
-
P/E prévisionnel
7.80
Croissance EPS
-8.21%
Informations sur les actions
Qu'est-ce qu'une bourse ? Fonctionnement, acteurs, exemples
Lire plusGraphique boursier
Loading...
Données du prix des actions
| Ouverture | 71.56 |
| Max journalier | 71.97 |
| Min journalier | 70.93 |
| Volume journalier | 2.09M |
| Niveau record | 109.62 |
| Estimation des analystes sur 1 an | 94.06 |
| Beta | 0.28 |
| EPS (TTM) | 5.65 |
| Dividende par action | 0.00 |
| Date ex-div | 5 May 2026 |
| Prochaine date de bénéfices | 23 Apr 2026 |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| SAN.PA | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -34.76% | -0.07% |
| Baisse de prix actuelle la plus importante | -55.80% | -56.47% |
| Date de la baisse la plus importante | 10 Oct 2008 | 9 Mar 2009 |
| Baisse moyenne par rapport au record | -19.76% | -10.67% |
| Délai moyen pour nouveau record | 44 days | 12 days |
| Délai max pour nouveau record | 2908 days | 1805 days |
Actualite
New digital leadership at Vallourec Vallourec (ENXTPA:VK) has appointed Isabelle Quéméneur as Group Chief Digital and Information Officer, adding her to the Executive Committee as of 5 October 2026 af...
8 octobre 2026
Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
8 octobre 2026
At Veeva R&D and Quality Summit on October 20-21 in Boston, Veeva Systems (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, CROs, and sites — including Duke University, Eli Lilly...
8 octobre 2026
European equities traded in the US as American depositary receipts fell late Wednesday morning with
7 octobre 2026
Report Forecasts Plozasiran Sales Through 2034 Across Severe Hypertriglyceridemia, Familial Chylomicronemia Syndrome and Mixed Hyperlipidemia, Following Sanofi's Greater China Licensing DealDublin, Oc...
7 octobre 2026
In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 bil...
6 octobre 2026
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th...
6 octobre 2026
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi....
6 octobre 2026
(OTC PINK:VICP) ("VICP" or the "Company") today announced that FutureBrand, the global brand consultancy behind the corporate identities of Sanofi, GSK and Merck, has onboarded the Company as a client...
5 octobre 2026